WuXi AppTec, a Chinese provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, agreed to acquire the remaining stake in Oxford Genetics, a cell and gene therapy provider, from Mercia Asset Management, a regionally focused specialist asset manager, for £31m. "We are delighted to welcome Oxgene to WuXi ATU. By combining WuXi ATU’s world-class cell and gene therapy CTDMO platform with Oxgene’s innovative capabilities, we will be able to provide transformative solutions for our customers. This business combination represents a significant step in our ongoing effort to enable our customers and partners worldwide to deliver more effective and accessible advanced therapies to patients globally," David Chang, WuXi AT CEO.